Lymphopaenia, anti-Ro/Anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus

Acta Dermato-Venereologica

Volumn 93, Issue 3, 2013, Pages 314-318

  Hu, Stephen Chu Sung ^a   Lin L , Chi Ling ^a   Lu, Yi Wei ^b   Chen, Gwo Shing ^a,c   Yu, Hsin Su ^a,c   Wu, Ching Shuang ^d   Lan, Cheng Che E ^a,c,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Graduate Institute of Healthcare Administration   (Taiwan)

^c School of Medicine   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Herpes zoster; Risk factors; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LA ANTIBODY; METHOTREXATE; PREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMOLYTIC ANEMIA; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84876995602     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1454     Document Type: Article

References (63)

1. Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007; 57: S130-S135.
2. Lee PP, Lee TL, Ho MH, Wong WH, Lau YL. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. Pediatr Infect Dis J 2006; 25: 728-732.
3. Kang TY, Lee HS, Kim TH, Jun JB, Yoo DH. Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol Int 2005; 25: 97-102.
4. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980; 30: 582-587.
5. Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983; 309: 1362-1368.
6. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992; 166 Suppl 1: S35-S41.
7. Terada K, Tanaka H, Kawano S, Kataoka N. Specific cellular immunity in immunocompetent children with herpes zoster. Acta Paediatr 1998; 87: 692-694.
8. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan C Y, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188: 1336-1344.
9. Urman CO, Gottlieb AB. New viral vaccines for derma-tologic disease. J Am Acad Dermatol 2008; 58: 361-370.
10. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 1980; 65: 869-878.
11. Gershon AA, Steinberg SP. Antibody responses to varicella-zoster virus and the role of antibody in host defense. Am J Med Sci 1981; 282: 12-17.
12. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yo-shikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990; 49: 630-633.
13. Horwitz DA. Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum 1972; 15: 353-359.
14. Andrianakos AA, Tsichlis PN, Merikas EG, Marketos SG, Sharp JT, Merikas GE. Cell-mediated immunity in systemic lupus erythematosus. Clin Exp Immunol 1977; 30: 89-96.
15. Pons VG, Reinertsen JL, Steinberg AD, Dolin R. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol 1979; 4: 15-23.
16. Kammer GM, Stein RL. T lymphocyte immune dysfunctions in systemic lupus erythematosus. J Lab Clin Med 1990; 115: 273-282.
17. Pascual-Ramos V, Hernández-Cruz B, Villalobos I, Sifuen-tes-Osornio J, Alcocer-Varela J. Purifed protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity. Lupus 2002; 11: 25-30.
18. Blaese RM, Grayson J, Steinberg AD. Increased immu-noglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 1980; 69: 345-350.
19. Nagasawa K, Yamauchi Y, Tada Y, Tsukamoto H, Mayumi T, Niho Y. High levels of antibody to varicella-zoster virus in systemic lupus erythematosus. J Infect Dis 1992; 166: 692-694.
20. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
21. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5 Suppl 4: S22-S27.
22. Criscione LG, Pisetsky DS. B lymphocytes and systemic lupus erythematosus. Curr Rheumatol Rep 2003; 5: 264-269.
23. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13: 381-390.
24. Ishikawa O, Abe M, Miyachi Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Der-matol 1999; 24: 327-328.
25. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
26. Taiwanese National Health Insurance Bureau. Available from: http://www.nhi.gov.tw/.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Roth-feld NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
28. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
29. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197 Suppl 2: S228-S236.
30. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197: 825-835.
31. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145: 317-325.
32. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280-1288.
33. Kahl LE. Herpes zoster infections in systemic lupus ery-thematosus: risk factors and outcome. J Rheumatol 1994; 21: 84-86.
34. Manzi S, Kuller LH, Kutzer J, Pazin GJ, Sinacore J, Meds-ger TA Jr, Ramsey-Goldman R. Herpes zoster in systemic lupus erythematosus. J Rheumatol 1995; 22: 1254-1258.
35. Janeway CA, Travers P, Walport M, Shlomchik M. Immu-nobiology - the immune system in health and disease. 6th edn. New York: Garland Publishing; 2005.
36. Mittal KK, Rossen RD, Sharp JT, Lidsky MD, Butler WT. Lymphocyte cytotoxic antibodies in systemic lupus ery-thematosus. Nature 1970; 225: 1255-1256.
37. Winfeld JB, Winchester RJ, Kunkel HJ. Proceedings: various types of antilymphocyte antibodies in patients with systemic lupus erythematosus (SLE) and their relationship with lymphopenia. Arthritis Rheum 1975; 18: 284-285.
38. Winfeld JB, Winchester RJ, Kunkel HG. Association of cold-reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 587-594.
39. Winfeld JB. Anti-lymphocyte antibodies in systemic lupus erythematosus. Clin Rheum Dis 1985; 11: 523-549.
40. Peake PW, Greenstein JD, Timmermans V, Gavrilovic L, Charlesworth JA. Lymphocytotoxic antibodies in systemic lupus erythematosus: studies of their temperature dependence, binding characteristics, and specificity in vitro. Ann Rheum Dis 1988; 47: 725-732.
41. Winfeld JB, Fernsten PD, Czyzyk JK. Anti-lymphocyte autoantibodies in systemic lupus erythematosus. Trans Am Clin Climatol Assoc 1997; 108: 127-135.
42. Bohm I. Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythemato-sus. Scand J Rheumatol 2004; 33: 409-416.
43. Wenzel J, Gerdsen R, Uerlich M, Bauer R, Bieber T, Boehm I. Antibodies targeting extractable nuclear antigens: historical development and current knowledge. Br J Dermatol 2001; 145: 859-867.
44. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005; 38: 55-63.
45. Wolin SL, Reinisch KM. The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev 2006; 5: 367-372.
46. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38: 47-54.
47. Wenzel J, Gerdsen R, Uerlich M, Bauer R, Tueting T, Bieber T. Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol 2004; 150: 994-998.
48. Silva LM, Garcia AB, Donadi EA. Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neu-ropsychiatric manifestations. J Neurol 2002; 249: 1048-1054.
49. Vilá LM, Alarcón GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD; Lumina Study Group. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006; 55: 799-806.
50. García-Valladares I, Atisha-Fregoso Y, Richaud-Patin Y, Jakez-Ocampo J, Soto-Vega E, Elías-López D, et al. Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus 2006; 15: 600-605.
51. Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompa-tibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 1989; 32: 826-836.
52. Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononu-clear cells through Fc receptors. Nature 1978; 271: 67-69.
53. Ma J, Chapman GV, Chen SL, Melick G, Penny R, Breit SN. Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG. Clin Exp Immunol 1991; 84: 83-91.
54. Ma J, King N, Chen SL, Penny R, Breit SN. Antibody penetration of viable human cells. II. Anti-RNP antibodies binding to RNP antigen expressed on cell surface, which may mediate the antibody internalization. Clin Exp Immunol 1993; 93: 396-404.
55. Alascon-Segovia D. Proceedings of the Second International Conference on the penetration of autoantibodies into living cells. J Autoimmun 1998; 11: 509-510.
56. Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis. Semin Nephrol 1999; 19: 48-56.
57. Kewalramani R, Singh AK. Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens 2002; 11: 273-277.
58. Su W, Madaio MP. Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells. Semin Nephrol 2003; 23: 564-568.
59. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14: 19-24.
60. Bluestein HG, Zvaifer NJ. Antibodies reactive with central nervous system antigens. Hum Pathol 1983; 14: 424-428.
61. Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH. Autoantibodies in neuropsychiatric lupus. Autoim-munity 2002; 35: 79-86.
62. Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE. Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. J Hosp Infect 2012; 80: 162-167.
63. Lin YJ, Huang LM, Lee CY, Chih TW, Lee PL, Chang LY, et al. A seroepidemiological study of varicella-zoster virus in Taipei City. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1996; 37: 11-15.